Condition: Heart Failure · Sponsor: Baylor Research Institute
This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).
This description comes directly from the study's public registry record.
Aayla Jamil, MBBS MPH · 214-820-1675 · Aayla.Jamil@BSWHealth.org
Always discuss trial participation with your own doctor first.
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Active Not Recruiting |
| Baylor University Medical Center | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03383419